30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
Journal for ImmunoTherapy of Cancer volume 3, Article number: P234 (2015)
The 2014 expert consensus on high dose interleukin-2 (HD-IL-2) states that, “Treating a minimum number of patients per year is important, as quality depends upon familiarity and repetition” . The minimum annual volume of HD-IL-2 associated with relatively worse outcomes is not known.
We analyzed the National Inpatient Sample (NIS), one of the largest publicly-available in-patient dataset in United States (U.S.), which represents a 20% stratified random sample of discharges from all hospitals. The NIS is drawn from all States participating in Healthcare Cost and Utilization Project, and thus represents 95 percent of the U.S. population. Patients with melanoma and renal cell carcinoma (RCC) were identified by using the ICD9 diagnostic codes. From this sample, patients receiving HD-IL-2 were identified by ICD9 procedure code 00.15. Annual hospital volume was calculated using a unique hospital number, available in the dataset. Using Joinpoint regression analysis, which detects change in trend of in-patient mortality with change in annual hospital volume, the hospitals were classified in 3 volume categories (low, medium and high). Multivariate logistic regression was used to identify predictors of in-patient mortality controlling for confounders including age, sex, Charlson comorbidity index, RCC, calendar year, urban location and teaching status of hospital.
From 2003 to 2011, 29,532 patients (weighted number of patients) with RCC or melanoma who received HD-IL-2 were identified, and 124 died during hospitalization, while receiving HD-IL-2 (0.4%). Higher hospital volume was associated with lower in-patient mortality (Figure 1). The Joinpoint regression identified 3 categories of hospital by annual hospital volume (low: 1-40 per year, medium: 41-120 per year, high >120 per year), which had significant difference in in-patient mortality (0.83%, 0.29% and 0.13% respectively, p=0.0003). On multivariate analysis, the low volume hospitals were associated with higher odds of in-patient mortality (OR 6.1, 95% CI 1.6-23.2, p=0.003) as compared to high volume hospitals. Additionally, hospitals with annual volume of 1-20 per year had even higher rates of inpatient mortality (1.31% vs. 0.13%, p < 0.0001) and multivariate odds (OR 8.9, 95% CI 2.4-33.2, p=0.0006) as compared to high volume hospitals.
Lower annual hospital volume of HD-IL-2 is associated with higher HD-IL2 related in-patient mortality. Annual hospital volume of less than 20 treatments is associated with 9 time higher risk of in-patient mortality as compared to high volume hospitals.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Mehta, K., Appleman, L., Wang, H. et al. Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma. j. immunotherapy cancer 3 (Suppl 2), P234 (2015). https://doi.org/10.1186/2051-1426-3-S2-P234
- Renal Cell Carcinoma
- Charlson Comorbidity Index
- Annual Volume
- Time High Risk